News - Lyrica, Research

Filter

Current filters:

LyricaResearch

Popular Filters

Pfizer's Lyrica equals levetiracetam in patients with partial onset seizures

22-02-2013

Global pharma behemoth Pfizer (NYSE: PFE) has announced top-line results from a Phase III study showing…

LyricaNeurologicalPfizerPharmaceuticalResearch

Pfizer's Lyrica misses primary endpoint in seizure frequency trial; positive in fibromyalgia

20-11-2012

US pharma behemoth Pfizer (NYSE: PFE) revealed disappointing top-line results of a double-blind, placebo-controlled,…

LyricaNeurologicalPfizerPharmaceuticalResearch

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Pfizer's Lyrica positive in two post-marketing studies

23-07-2012

Top-line results for global drugs behemoth Pfizer's already marketed diabetic nerve pain and post-herpetic…

LyricaNeurologicalPfizerPharmaceuticalReproductiveResearch

Pfizer reports disappointment with Ph III trials of Lyrica in extended indications

08-05-2012

US drugs behemoth Pfizer (NYSE; PFE) had a setback with extending the use of its blockbuster drug Lyrica…

LyricaNeurologicalPfizerPharmaceuticalResearch

Pfizer out-licenses neratinib to Puma Biotech; stops Lyrica epilepsy trial on good efficacy

07-10-2011

In a second drug candidate sale this week, pharma behemoth Pfizer (NYSE: PFE) has agreed to sell rights…

FinancialLicensingLyricaNeurologicalOncologyPfizerPharmaceuticalPuma BiotechResearch

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top